Seb
@ibdseb
Followers
4K
Following
18K
Media
1K
Statuses
9K
IBD clinician& researcher @IBDHull. Governing Board :ECCO own views, RT🚫endorse.⚽️@LFC fan.
England
Joined August 2010
7
10
63
Great researcher and a nice person too
🔥WOW! Magnet speaker! Already more than 870 registrants from 88 countries 🔥 you can still join us! 👉🏽 https://t.co/OhHpSR3oUH 👈🏻 @SaraElOualiMD @CharlieMuz @AsadurRahman87 @MRegueiroMD @JosephHabibi_MD @IdoVeisman @BettenworthDb @KatieFalloonMD
0
1
7
This 👇 is a nice study And for the believers ie: anastomotic ulceration = CD recurrence gives more evidence to confirm belief And for those who are sceptical 🤨: does anastomotic ulcers matter 🤔 and even if it does do we risk over- treating with current available therapies
Our work on post-operative #crohns: Biopsies from the ileum, anastomosis and colon: Inflammation at the anastomosis is the same as inflammation in the colon/ileum, it is not hypoxia! should we treat? @JeanFredericCo1 @Bealoquebea @IBDimmunology
https://t.co/LIP9E7rnIi
2
4
10
📊 This is a comprehensive list of TL1A inhibitors compiled by Sleuth Insights. The market is getting ready for the new kid on the block 👀 — but the real question remains: ➡️ Will TL1A work for anti-TNF refractory patients? Exciting times ahead as we watch this space evolve.
1
3
24
🚨Just published in @UEGJournal 🤰🌍International survey on pregnancy in #IBD now out, ➡️current practices, perceptions, and unmet needs in managing IBD during pregnancy. Important collaborative study! 💪 @MJCasanovaG @jp_gisbert @maria_chs @JulsgaardMette
onlinelibrary.wiley.com
Background Reproduction is a fundamental aspect of life. This study aimed to provide an international overview of gastroenterologists' approaches to managing inflammatory bowel disease (IBD) during...
1
8
16
Common sense is needed to interpret science. PPIs are safe drugs, and if clinically well indicated are even safer with a very high signal/noise ratio (in fact it’s difficult to find safer drugs) 👇👇👇👇👇👇👇👇👇👇👇👇
“Evidence is inadequate to establish causal relationships between PPI therapy and many of the proposed associations”. The figure is not appropiate for a journal such as Gastroenterology @AmerGastroAssn
1
9
20
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn’s disease: A prospective observational study - Clinical Gastroenterology and Hepatology https://t.co/9Jf9d14POw
@EdwardLoftus2 @PeyrinBiroulet
@peter_bossuyt Includes contribution from @IbdHull
cghjournal.org
This post-authorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn’s disease (CD).
0
5
14
📣 We have reached half century of participants in @ACESO_ASUC study 🎉🎉 Massive thanks 🙏🏼to all the study sites , teams and importantly the patients Need to stay in the crease to hold the innings & go to the next big one 😊
0
0
7
While the idea is good, the methodology is weak—some points highlighted in a comment by Hanxiang Zhan, Shandong University Future work would benefit from better understanding of LLMs to producing impactful science This is the aim of @OPSORE
https://t.co/AliluP6cWQ
jamanetwork.com
This study evaluates the use of large language models in predicting surgical case length.
0
4
6
This letter to @thetimes by eminent Prof @MichaelBaum11 on prostate cancer screening should be disseminated far and wide ⬇️
1
15
31
Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial @RakeshKalapala1 @miNitinjagtap @DrDNReddy
https://t.co/uAFPWo9POQ
2
8
22
✨ Glad to share our original research article published in the Indian Journal of Gastroenterology! 📘 “Oral Semaglutide for Weight Loss and Liver Fibrosis in Overweight and Obesity: A Randomized Controlled Trial” (Indian J Gastroenterol, 2025 | DOI: 10.1007/s12664-025-01856-7)
3
11
51
Another recruit today to @ACESO_ASUC study 🎉🎉 The excellent #IBD team @SomersetFT led by @dremmaw & @alisongti have randomised their first participant Thanks 🙏🏼 to the participant and the whole team
1
1
13
What is the impact of ❓ GLP-1 analogues in Immune Mediated Inflammatory Disorders (IMIDs) including #IBD This 👇 comprehensive SR from our group led by @ChhaganBirda gives useful insights @drvishal82 @DrAnuraagJ
https://t.co/yq7DQb0W7p
1
12
30
This 👇 was produced by involving brilliant minds with enthusiasm and dedication to progress #IBD care and research in #LIMICs . We should focus and use this opportunity to really do impactful SELFLESS work including research 🔬 to really understand the biology 🧬 🧪 🧫 of
You don’t need to reinvent the wheel... Planning an #IBD project in LMICs? The ECCO consensus identifies key #research gaps & practical recommendations from authors across the globe— a valuable resource for researchers Read the open-access article https://t.co/Q5xcXOj65I
1
1
12
Support and encouragement to the #NextGen ↔️ impactful outcome Well done 👏
🔥 From Poster📰 to Paper🗞❗️ 💥I met @ishamaniyar29 at @DDWMeeting 2024 (#Washington, USA), where she presented her poster 💥She was in her 1️⃣ year of med school ✅I encouraged her to submit manuscript to @UEGJournal 💥Finally, her dream came true!🙏 🟢 @my_ueg 🟣 @Y_ECCO_IBD
0
0
4
Dr. Sebastian (@ibdseb), IBD Lead at @HullHospitals, highlights how a long-acting TL1A could transform care—offering greater convenience, helping patients live life on their terms. Learn about Vial’s half-life extended anti-TL1A: https://t.co/P9lHSfbf3Y
0
1
7
Congratulations to Maria Machado for winning the Nobel Peace Prize 🎉 The need for democratic elections in all offices is something we all should champion in our own little way so that democratic thinking is cascaded in all walks of life This applies to professional societies
WATCH LIVE: Join us for the 2025 Nobel Peace Prize announcement. Hear the breaking news first – see the live coverage from 11:00 CEST. Where are you watching from? #NobelPrize
https://t.co/1ftVKKETJm
0
2
11
Excellent 👌 Thanks to @IbdHull team @brezinabiljana & team @DrAKentGI & team 15 🇬🇧 sites recruiting ; 12 being set up - let us collectively deliver this clinically important study @CrohnsColitisUK
Fantastic 24 hours for the study as 3 additional participant recruited from sites Cambridge @@CUH_NHS Hull @IbdHull Kings college @KingsCollegeNHS Thanks to participants and teams @ibdseb
0
2
7
Unlock the future of surgery at Session 6 on Day 3: Artificial Intelligence in Surgery! From robotic assistance to AI-powered planning tools, get insider insights from the experts shaping tomorrow’s operating room. Seats are filling fast — reserve yours now!
1
3
4
This will be a unique session. Computer scientists meeting surgeons to present three innovative projects & discuss how to implement #AI in surgical innovations
Unlock the future of surgery at Session 6 on Day 3: Artificial Intelligence in Surgery! From robotic assistance to AI-powered planning tools, get insider insights from the experts shaping tomorrow’s operating room. Seats are filling fast — reserve yours now!
0
4
11